Single-Dose and Steady-State Pharmacokinetics of Doxazosin Given in Combination with Chlorothiazide to Hypertensive Subjects
The pharmacokinetics of doxazosin were determined in hypertensive subjects after a single dose of 1mg, and at steady-state while receiving doses of 1, 2, 4 and 8mg of the drug daily. Chlorothiazide 500mg once daily was administered as additional therapy throughout the study. After a single dose doxazosin was rapidly absorbed, with peak plasma drug concentrations (Cmax) occurring after 2.1 ± 0.4 hours. The elimination half-life in plasma was 10.7 ± 1.2 hours. These parameters remained essentially unchanged during maintenance administration of doxazosin at each of the dose levels. Calculations of Cmax and area under the concentration-time curve (A UC0→∞) indicated that the pharmacokinetic disposition of the drug remained linear over the dose range 1 to 8mg.
KeywordsClinical Pharmacology Prazosin Doxazosin Hypertensive Subject Terazosin
Unable to display preview. Download preview PDF.
- Lund-Johansen P. Hemodynamic changes at rest and during exercise in long-term prazosin therapy for essential hypertension. Postgraduate Medical Journal 58 (Suppl.): 45–52, 1975Google Scholar
- Stokes GS. Prazosin. In Doyle AE (Ed.) Clinical pharmacology of antihypertensive drugs, Handbook of Hypertension, Vol. 5, pp. 350–375, Elsevier, Amsterdam, 1984Google Scholar
- Wagner JG. Biopharmaceutics and relevant pharmacokinetics. In Drug Intelligence Publications, pp. 242–246, Hamilton Press, Hamilton, Illinois, 1971Google Scholar